TATA健康(01255.HK)擬4100萬港元出售香港新界物業
格隆匯12月31日丨TATA健康(01255.HK)公吿,於2021年9月27日,賣方(公司一間間接全資附屬公司)與買方訂立意向書,當中載列條款及條件,據此買方原則上有意購買由賣方持有的若干物業,獨家期間由意向書日期起直至2021年12月31日止。買方於簽署意向書時,已向賣方支付300萬港元的誠意金。
董事會欣然宣佈,於2021年12月31日,賣方與買方訂立正式協議,據此賣方須出售,而買方須向賣方收購該等物業,代價為4100萬港元,惟受下文"條件"一段的條件及條款所限。
賣方亦同意將該等物業(第51號停車位除外)租予集團,年度租金為170.4萬港元,由完成日期起為期一年。
"該等物業"指由位於香港新界葵涌葵德街15–33號葵德工業中心2座6樓工作間A、B、C、D及E,以及地下第51號停車位組成的該等物業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.